Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (311-320 of 319) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 319 results.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancerJames Mohler, Robert R Bahnson, Barry Boston, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Cancer Discovery|January 6, 2018
An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate CancerDavid T Miyamoto, Richard J Lee, Mark Kalinich, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Lancet (London, England)|November 1, 2025
The 2025 report of the Lancet Countdown on health and climate change: climate change action offers a lifelineMarina Romanello, Maria Walawender, Shih-Che Hsu, et al.
Pageof 32

Showing results (311-320 of 319) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 319 results.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
The Oncologist|February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMISNeal D Shore, Christian Gratzke, Susan Feyerabend, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancerJames Mohler, Robert R Bahnson, Barry Boston, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
JCO Oncology Practice|December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is NowNeal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Cancer Discovery|January 6, 2018
An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate CancerDavid T Miyamoto, Richard J Lee, Mark Kalinich, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Lancet (London, England)|November 1, 2025
The 2025 report of the Lancet Countdown on health and climate change: climate change action offers a lifelineMarina Romanello, Maria Walawender, Shih-Che Hsu, et al.
Pageof 32